Factors predicting biochemical response and survival benefits following radioligand therapy with [(177)Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review

por Manafi-Farid, Reyhaneh, Harsini, Sara, Saidi, Bahare, Ahmadzadehfar, Hojat, Herrmann, Ken, Briganti, Alberto, Walz, Jochen, Beheshti, Mohsen
Publicado 2021